#1 Clinical Trials Search in Europe

XYLOMETAZOLINE HYDROCHLORIDE

Clinical trials investigating XYLOMETAZOLINE HYDROCHLORIDE are studying how it is used in specific patient groups, including people with COPD and patients needing intranasal pain control for nasotracheal intubation. These trials mainly look at physical capacity, pain relief, and study design in Phase 3 interventional research.

Table of Contents

Trial overview

These records describe interventional clinical trials, which means researchers gave a treatment or procedure and then measured the results.[1][2] The trials investigate XYLOMETAZOLINE HYDROCHLORIDE in two different clinical settings: COPD and nasotracheal intubation.[1][2] Both studies are in Phase 3, which is a later stage of testing in people.[1][2]

COPD study and physical capacity

One trial, NCT 2024-520177-12-00, is an authorised Phase 3 study in people with Chronic Obstructive Pulmonary Disease (COPD).[1] Its goal is to assess the effect of one dose on the physical capacity of patients with COPD.[1] The main result being measured is walking distance, which helps show how far a person can walk as a sign of physical ability.[1]

Intranasal analgesia study during nasotracheal intubation

The second trial, NCT 2023-506644-17-01, is a completed Phase 3 blinded triple crossover study in patients undergoing nasotracheal intubation.[2] A blinded triple crossover study means the treatment order is compared across several approaches, and the people involved do not know which treatment is being given at a given time.[2] This study compares cocaine, lidocaine/xylometazoline, and saline for intranasal analgesia, which means pain relief given through the nose.[2]

Study design and participants

The COPD study includes patients with a long-term lung disease that can make breathing difficult.[1] The intubation study includes patients who need a breathing tube placed through the nose.[2] Together, these trials show that XYLOMETAZOLINE HYDROCHLORIDE is being studied in very different groups of patients rather than in one single disease area.[1][2]

Endpoints and outcome measures

A primary outcome is the main result a study is designed to measure.[1][2] In the COPD study, the primary outcome is walking distance.[1] In the intubation study, the primary outcome is self-reported pain during the procedure, measured with a visual analogue scale from 0 to 100.[2] This scale is a simple way for patients to rate pain, with higher numbers showing more pain.[2]

Trial status and enrollment

The COPD study is listed as Authorised and plans to include 64 participants.[1] The intranasal analgesia study is listed as Completed and included 12 participants.[2] Enrollment means the number of people planned or included in a study.[1][2]

Trial ID Phase Condition studied Status Enrollment
2024-520177-12-00 Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Authorised 64
2023-506644-17-01 Phase 3 Nasotracheal intubation Completed 12

FAQ

  • What is being studied in trials of XYLOMETAZOLINE HYDROCHLORIDE? The trials focus on how XYLOMETAZOLINE HYDROCHLORIDE is used in patient care settings, such as intranasal analgesia and related nasal spray studies. The main outcomes are walking distance and self-reported pain.
  • Who can take part in these trials? One trial includes patients with Chronic Obstructive Pulmonary Disease (COPD). Another trial includes patients undergoing nasotracheal intubation, which is a procedure where a breathing tube is placed through the nose.
  • What phase are the trials? Both trials are Phase 3 studies. Phase 3 trials usually test a treatment in a larger group of people to better understand its effects.
  • What results are the trials measuring? One trial measures walking distance to assess physical capacity. The other measures pain during the procedure using a visual scale from 0 to 100.
  • Are these trials already finished? One trial is authorised and the other is completed. This means the studies have been approved or already ended.

Ongoing Clinical Trials on XYLOMETAZOLINE HYDROCHLORIDE

  • Study on the Effect of Xylometazoline Nasal Spray on Physical Capacity in Adults with Chronic Obstructive Pulmonary Disease (COPD)

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on Nasal Pain Relief for Patients Undergoing Nasotracheal Intubation Using Cocaine, Lidocaine/Xylometazoline, and Saline

    Not recruiting

    3 1 1
    Investigated drugs:
    Denmark

Glossary

  • Clinical trial: A research study in people that tests a treatment, procedure, or care approach.
  • Interventional study: A study where researchers give a treatment or procedure and then measure the results.
  • Phase 3: A later stage of clinical testing that usually includes more participants and checks how well a treatment works.
  • Chronic Obstructive Pulmonary Disease (COPD): A long-term lung disease that can make breathing difficult.
  • Nasotracheal intubation: A procedure where a breathing tube is placed through the nose into the airway.
  • Intranasal: Given through the nose.
  • Primary outcome: The main result a study is designed to measure.
  • Walking distance: How far a person can walk, used here as a measure of physical capacity.
  • Visual analogue scale: A simple rating tool, often from 0 to 100, used to measure pain or other symptoms.
  • Enrollment: The number of people planned or included in a study.

References

  1. https://clinicaltrials.gov/study/2024-520177-12-00
  2. https://clinicaltrials.gov/study/2023-506644-17-01